Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 8/20 | 0.37 |
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617062 | 0.88 | CTSK (0.41) | CTSKGSTP1GSTM2KLK5CTSS | |
| SCHEMBL3617063 | 0.88 | CTSK (0.41) | CTSKGSTP1GSTM2KLK5CTSS | |
| SCHEMBL4745237 | 0.88 | CTSK (0.41) | CTSKGSTP1GSTM2KLK5CTSS | |
| SCHEMBL17271823 | 0.85 | CTSK (0.42) | CTSKGSTP1GSTM2KLK5CTSS | |
| SCHEMBL23177271 | 0.85 | CTSK (0.42) | CTSKGSTP1GSTM2KLK5CTSS | |
| SCHEMBL2480209 | 0.81 | CTSK (0.43) | CTSKKLK5CTSSCTSLCYP1A2 | |
| SCHEMBL26968991 | 0.80 | CTSK (0.41) | CTSKCTSSCTSLCYP1A2CYP2C9 | |
| SCHEMBL29548094 | 0.80 | CTSK (0.41) | CTSKCTSSCTSLCYP1A2CYP2C9 | |
| SCHEMBL15746588 | 0.79 | CTSK (0.48) | CTSKKLK5CTSSCTSLCYP1A2 | |
| SCHEMBL3198135 | 0.79 | CA1 (0.42) | CTSKGSTP1GSTM2KLK5CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250137-A1 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110250137-A1 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| EP-2373597-A2 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION | Bayer Pharma Aktiengesellschaft (DE) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010063403-A2 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250137-A1 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION | ODC1, OTC, ARG1 | CTSK 257/4885GSTP1 3155/4885GSTM2 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.